This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sankala, H. M. Articles by Spiegel, S. Search for Related Content PubMed PubMed Citation Articles by Sankala, H. M. Articles by Spiegel, S.

Involvement of Sphingosine Kinase 2 in p53-Independent Induction of p21 by the Chemotherapeutic Drug Doxorubicin

Departments of ¹ Biochemistry and Molecular Biology and ² Pathology and the Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia and ³ National Institute of Mental Health, Bethesda, Maryland

Requests for reprints: Sarah Spiegel, Department of Biochemistry and Molecular Biology, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0614. Phone: 804-828-9330; Fax: 804-828-8999; E-mail: sspiegel{at}vcu.edu.

Sphingosine-1-phosphate is a potent lipid mediator formed by phosphorylation of sphingosine, a metabolite of sphingolipids, catalyzed by two sphingosine kinase (SphK) isoenzymes, SphK1 and SphK2. Expression of SphK2, which is enriched in the nucleus of MCF7 human breast cancer cells, increased expression of the cyclin-dependent kinase inhibitor p21 but had no effect on p53 or its phosphorylation. The anticancer drug doxorubicin is known to increase p21 via p53-dependent and p53-independent mechanisms. Down-regulation of endogenous SphK2 with small interfering RNA targeted to unique mRNA sequences decreased basal and doxorubicin-induced expression of p21 without affecting increased expression of p53. Down-regulation of SphK2 also decreased G₂-M arrest and markedly enhanced apoptosis induced by doxorubicin. Moreover, siSphK2 reduced doxorubicin-induced p21 expression in p53-inactivated MCF7 cells. Likewise, in human wild-type p53- and p21-expressing HCT116 colon carcinoma cells, as well as in p53-null counterparts, down-regulation of SphK2 markedly reduced p21 induction by doxorubicin. Knockdown of SphK2 sensitized HCT116 cells to apoptosis induced by doxorubicin with concomitant cleavage of poly(ADP-ribose) polymerase. Collectively, our results show that endogenous SphK2 is important for p53-independent induction of p21 expression by doxorubicin and suggest that SphK2 may influence the balance between cytostasis and apoptosis of human cancer cells. [Cancer Res 2007;67(21):10466–74]

This article has been cited by other articles:

				W. D. Meacham, J. W. Antoon, M. E. Burow, A. P. Struckhoff, and B. S. Beckman Sphingolipids as Determinants of Apoptosis and Chemoresistance in the MCF-7 Cell Model System Experimental Biology and Medicine, November 1, 2009; 234(11): 1253 - 1263. [Abstract] [Full Text] [PDF]

				P. D. Ottewell, J. K. Woodward, D. V. Lefley, C. A. Evans, R. E. Coleman, and I. Holen Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone Mol. Cancer Ther., October 1, 2009; 8(10): 2821 - 2832. [Abstract] [Full Text] [PDF]

				N. C. Hait, J. Allegood, M. Maceyka, G. M. Strub, K. B. Harikumar, S. K. Singh, C. Luo, R. Marmorstein, T. Kordula, S. Milstien, et al. Regulation of Histone Acetylation in the Nucleus by Sphingosine-1-Phosphate Science, September 4, 2009; 325(5945): 1254 - 1257. [Abstract] [Full Text] [PDF]

				D. Kapitonov, J. C. Allegood, C. Mitchell, N. C. Hait, J. A. Almenara, J. K. Adams, R. E. Zipkin, P. Dent, T. Kordula, S. Milstien, et al. Targeting Sphingosine Kinase 1 Inhibits Akt Signaling, Induces Apoptosis, and Suppresses Growth of Human Glioblastoma Cells and Xenografts Cancer Res., September 1, 2009; 69(17): 6915 - 6923. [Abstract] [Full Text] [PDF]

				S. M. K. Pulukuri, J. A. Knost, N. Estes, and J. S. Rao Small Interfering RNA-Directed Knockdown of Uracil DNA Glycosylase Induces Apoptosis and Sensitizes Human Prostate Cancer Cells to Genotoxic Stress Mol. Cancer Res., August 1, 2009; 7(8): 1285 - 1293. [Abstract] [Full Text] [PDF]

				J. S. Karliner Sphingosine kinase regulation and cardioprotection Cardiovasc Res, May 1, 2009; 82(2): 184 - 192. [Abstract] [Full Text] [PDF]

				S. Nemoto, M. Nakamura, Y. Osawa, S. Kono, Y. Itoh, Y. Okano, T. Murate, A. Hara, H. Ueda, Y. Nozawa, et al. Sphingosine Kinase Isoforms Regulate Oxaliplatin Sensitivity of Human Colon Cancer Cells through Ceramide Accumulation and Akt Activation J. Biol. Chem., April 17, 2009; 284(16): 10422 - 10432. [Abstract] [Full Text] [PDF]

				K. Takabe, S. W. Paugh, S. Milstien, and S. Spiegel "Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets Pharmacol. Rev., June 1, 2008; 60(2): 181 - 195. [Abstract] [Full Text] [PDF]